HP cohorts, MAD
TEAEs
Ten of 12 (83.3%) HPs who received a repeat dose of ARO-ANG3 reported at least one TEAE, with a total of 44 reported TEAEs (Table TEAEs reported in more than one participant are presented in Extended Data Table 